Two-negative and one-positive breast cancer refers to a state in which the pathological examination of breast cancer shows immunohistochemical results that are negative for estrogen receptor (ER) and negative for progesterone receptor (PR), while the expression of human epidermal growth factor receptor-2 (Her-2) gene is strongly positive. In general, patients who present with positive epidermal growth factor receptor-2 gene amplification are somewhat more malignant and have a relatively high recurrence rate compared to patients who are estrogen receptor and progesterone receptor positive. This situation of two negatives and one positive immunohistochemistry suggests that post-surgical treatment is not suitable for endocrine therapy and genetic testing is needed to treat with targeted drugs targeting the epidermal growth factor receptor-2 gene, as it is more prone to recurrence progression in the process of disease progression and should be given more aggressive treatment. In addition, breast cancer is a systemic disease and the high or low recurrence rate cannot be judged by the immunohistochemistry results alone. The specific recurrence rate is related to the clinical stage of breast cancer, the treatment plan, the patient’s sensitivity to treatment, whether to adhere to regular review, the patient’s age and other factors. It is recommended to choose the appropriate treatment plan and cooperate with the doctor for active treatment under the guidance of the doctor.